INTERNATIONAL PATENT: PFIZER INC. FILES APPLICATION FOR "COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES"

GENEVA, Aug. 4 -- PFIZER INC. (66 Hudson Boulevard EastNew York, New York 10001-2192) filed a patent application (PCT/IB2025/050625) for "COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES" on Jan 22, 2025. With publication no. WO/2025/158284, the details related to the patent application was published on Jul 31, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): DULLEA, Robert Gregory (c/o Pfizer Inc.610 Main StreetCambridge, Massachusetts 02139), FILIPSKI, Kevin James (c/o Pfizer Inc.610 Main StreetCambridge...